Lucentis(ranibizumab)
Byooviz, Cimerli, Lucentis, Susvimo (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat degenerative myopia, diabetes complications, diabetic retinopathy, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A. In addition, it is known to target Vascular endothelial growth factor A.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Byooviz, Cimerli, Lucentis, Susvimo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diabetic retinopathy | EFO_0003770 | D003930 | — |
| macular edema | — | D008269 | — |
| retinal vein occlusion | EFO_1001157 | D012170 | H34.81 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ranibizumab, Cimerli, Coherus BioSciences, Inc. | |||
| Date TBD | Interchangeable excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg |
Clinical
Clinical Trials
524 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 28 | 71 | 62 | 37 | 31 | 205 |
| Macular edema | D008269 | 17 | 47 | 32 | 24 | 24 | 128 | ||
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 10 | 10 | 18 | 14 | 10 | 56 |
| Choroidal neovascularization | D020256 | 5 | 15 | 9 | 6 | 1 | 33 | ||
| Diabetic retinopathy | D003930 | EFO_0003770 | 2 | 12 | 7 | 8 | 2 | 29 | |
| Wet macular degeneration | D057135 | EFO_0004683 | — | 5 | 3 | 4 | 1 | 12 | |
| Retinal neovascularization | D015861 | H35.05 | 3 | 5 | 3 | 2 | 1 | 12 | |
| Vision disorders | D014786 | HP_0000505 | H53.11 | — | — | 4 | 3 | 1 | 8 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 3 | 2 | 1 | 2 | — | 7 |
| Neovascular glaucoma | D015355 | EFO_1001060 | 1 | 2 | 2 | 2 | 1 | 7 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | 1 | 3 | — | 5 | 9 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 2 | 3 | 2 | — | 2 | 6 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | 2 | 2 | 1 | — | — | 4 |
| Pterygium | D011625 | H11.0 | 2 | 1 | 1 | — | — | 3 | |
| Degenerative myopia | D047728 | H44.2 | 2 | 1 | 1 | — | — | 3 | |
| Diabetes complications | D048909 | — | 1 | 1 | — | 1 | 2 | ||
| Retinal hemorrhage | D012166 | HP_0000573 | H35.6 | 1 | 1 | 1 | — | — | 2 |
| Diffuse cerebral sclerosis of schilder | D002549 | Orphanet_726 | G31.81 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Telangiectasis | D013684 | 4 | 1 | — | — | — | 5 | ||
| Von hippel-lindau disease | D006623 | Q85.83 | 3 | 2 | — | — | — | 3 | |
| Retinal degeneration | D012162 | HP_0001105 | 2 | 1 | — | — | — | 2 | |
| Retinal telangiectasis | D058456 | Orphanet_190 | H35.02 | 1 | 1 | — | — | 1 | 2 |
| Ischemia | D007511 | EFO_0000556 | 2 | 1 | — | — | — | 2 | |
| Retinal dystrophies | D058499 | Orphanet_71862 | — | 1 | — | — | — | 1 | |
| Diabetic angiopathies | D003925 | EFO_1000896 | 1 | 1 | — | — | — | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | 1 | — | — | — | 1 |
| Retinal perforations | D012167 | EFO_1001028 | — | 1 | — | — | — | 1 | |
| Retinoblastoma | D012175 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal neovascularization | D016510 | EFO_1000880 | H16.4 | 2 | — | — | — | — | 2 |
| Hereditary hemorrhagic telangiectasia | D013683 | I78.0 | 1 | — | — | — | — | 1 | |
| Epistaxis | D004844 | EFO_0003895 | R04.0 | 1 | — | — | — | — | 1 |
| Depression | D003863 | F33.9 | 1 | — | — | — | — | 1 | |
| Port-wine stain | D019339 | Q82.5 | 1 | — | — | — | — | 1 | |
| Neurofibromatosis 1 | D009456 | Q85.01 | 1 | — | — | — | — | 1 | |
| Neurofibroma | D009455 | EFO_0000622 | 1 | — | — | — | — | 1 | |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | — | — | — | 1 |
| Blister | D001768 | 1 | — | — | — | — | 1 | ||
| Ischemic optic neuropathy | D018917 | EFO_1000809 | H47.01 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intraocular pressure | D007429 | — | — | — | — | 1 | 1 | ||
| Regional blood flow | D012039 | — | — | — | — | 1 | 1 | ||
| Cataract extraction | D002387 | — | — | — | — | 1 | 1 | ||
| Premature infant diseases | D007235 | — | — | — | — | 1 | 1 | ||
| Geographic atrophy | D057092 | — | — | — | — | 1 | 1 | ||
| Researcher-subject relations | D035844 | — | — | — | — | 1 | 1 | ||
| Epiretinal membrane | D019773 | HP_0100014 | — | — | — | — | 1 | 1 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
| Retinal arterial macroaneurysm | D000080346 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RANIBIZUMAB |
| INN | ranibizumab |
| Description | Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 kappa-chain |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >1CZ8:H,Y|HEAVY CHAIN OF NEUTRALIZING ANTIBODY
EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
LQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL
>1CZ8:L,X|LIGHT CHAIN OF NEUTRALIZING ANTIBODY
DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 1CZ8 |
| CAS-ID | 347396-82-1 |
| RxCUI | 595060 |
| ChEMBL ID | CHEMBL1201825 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01270 |
| UNII ID | ZL1R02VT79 (ChemIDplus, GSRS) |
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Cimerli - Coherus BioSciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Byooviz - Biogen
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lucentis - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lucentis - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,229 documents
View more details
Safety
Black-box Warning
Black-box warning for: Susvimo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,731 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more